A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2004 |
| End Date: | December 2014 |
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a
new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is
the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is
the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
Inclusion Criteria:
- Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse
large cell non-Hodgkin's lymphoma, histologically or cytologically proven at
diagnosis which is refractory to or intolerant of established therapy know to provide
clinical benefit for their condition; tumors must express Rb
- Adequate blood cell counts, kidney function and liver function and and ECOG score of
0, 1, or 2.
- Patients may have to have tumor biopsy before and after treatment.
Exclusion Criteria:
- Prior stem cell or bone marrow transplant
- Uncontrolled infection, unstable or sever intercurrent medical condition, or current
drug or alcohol abuse
- Active or unstable cardiac disease or history of heart attack within 6 months
We found this trial at
4
sites
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials